0001171843-24-001893.txt : 20240408 0001171843-24-001893.hdr.sgml : 20240408 20240408070006 ACCESSION NUMBER: 0001171843-24-001893 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XORTX Therapeutics Inc. CENTRAL INDEX KEY: 0001729214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40858 FILM NUMBER: 24828148 BUSINESS ADDRESS: STREET 1: SUITE 2400 - 745 THURLOW STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 0C5 BUSINESS PHONE: 403-607-2621 MAIL ADDRESS: STREET 1: SUITE 2400 - 745 THURLOW STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 0C5 6-K 1 f6k_040824.htm FORM 6-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2024

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  XORTX Therapeutics Inc.    
   (Registrant)
    
   
Date: April 8, 2024 By:     /s/ Allen Davidoff    
  Name: Allen Davidoff
  Title: Chief Executive Officer
   

EXHIBIT INDEX 

99.1 News release dated April 8, 2024
 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

XORTX Announces Participation in Spring 2024 Investor Conferences

CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, CEO, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences:

  • LD Micro Invitational XIV in New York, April 8-9
    Management will deliver a corporate update on April 9th at 2:00 p.m. ET and will be available for one-on-one meetings.
    Registration link:
  • Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, April 17-18
    Management will deliver a virtual presentation and will be available for virtual one-on-one meetings.
    Registration Link:
  • CEM Scottsdale Capital Event in Scottsdale, April 19-21
    Management will deliver a corporate update and be available for one-on-one meetings.
    Registration Link:
  • BIO International Convention in San Diego, June 3-6
    Management will make presentations to prospective investors and partners during one-on-one meetings.

Additional information on how to listen to webcast presentations, where available, will be announced at a later date.

The Company also announces it has engaged LHA Investor Relations for investor relations services for a fee of US$15,000 per month. The LHA Investor Relations agreement is for a term of six months, renewable by mutual consent and can be terminated by XORTX on 30 days’ notice.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.

For more information, please contact: 
  
Allen Davidoff, CEONick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727nick@alpineequityadv.com or +1 617 901 0785
  
Kim Golodetz, LHA Investor Relations 
kgolodetz@lhai.com or 1 212 838 3777 
  

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.